title: Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register.
abstract: OBJECTIVE
  Retinopathy of prematurity (ROP) is a sight-threatening disease, requiring efficient screening and treatment. The present study aims to describe various aspects on treatment for ROP in Sweden.
  
  
  METHODS
  Data on treatment for ROP in infants born in 2008-2012 were extracted from Swedish national register for retinopathy of prematurity, a web-based national register.
  
  
  RESULTS
  During 2008-2012, 3488 infants with a gestational age (GA) at birth of <31 weeks had been screened for ROP in Sweden. Altogether, 30.3% (1057/3488) of the infants developed ROP and 5.2% (181/3488) were treated. Type 1 ROP was found in at least one eye in 83.2% (149/179) of the treated infants. One third of the eyes (32.2% right, 29.9% left eyes) were treated more than once. Laser was the only treatment in 90% of the eyes. Mean number of laser spots at first laser session was 1177 and 1386 in right and left eyes, respectively. Number of laser spots correlated negatively with GA at birth (p=0.01). There was no change in frequency of treatment or number of laser spots during the 5-year period. Anti-vascular endothelial growth factor injections were performed in 28 eyes, encircling band was used in five eyes and vitrectomies were performed in seven eyes. Twenty-six retinal surgeons performed 9.4 (range 1-37) treatment sessions in the 181 infants.
  
  
  CONCLUSIONS
  The present study reveals similar incidences of ROP and frequencies of treatment during the 5-year study period. Many surgeons were involved in treatment of a rather limited number of infants. The results call for national discussions on organisation of ROP treatment.
authors.affiliation: Department of Neuroscience/ophthalmology, Uppsala University, Uppsala, Sweden.
authors.forename: Gerd
authors.initials: G
authors.lastname: Holmström
authors.affiliation: Section of Pediatric Ophthalmology, The Queen Silvia Children's Hospital, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
authors.forename: Ann
authors.initials: A
authors.lastname: Hellström
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
authors.forename: Peter
authors.initials: P
authors.lastname: Jakobsson
authors.affiliation: Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden.
authors.forename: Pia
authors.initials: P
authors.lastname: Lundgren
authors.affiliation: Department of Ophthalmology, Lund University Hospital, Lund, Sweden.
authors.forename: Kristina
authors.initials: K
authors.lastname: Tornqvist
authors.affiliation: St. Erik Eye Hospital, Stockholm, Sweden.
authors.forename: Agneta
authors.initials: A
authors.lastname: Wallin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D001724:Birth Weight; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods*; D011159:Population Surveillance / Q000379:methods; D011379:Prognosis; D019984:Quality Indicators, Health Care; D012042:Registries; D012178:Retinopathy of Prematurity / Q000453:epidemiology / Q000628:therapy*; D012189:Retrospective Studies; D013548:Sweden / Q000453:epidemiology; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A
keywords: Child health (paediatrics); Retina